Facebook
X
LinkedIn
ForwardMayo Clinic Proceedings - Alzheimer Disease: Scientific Breakthroughs and Translational Challenges (June 1, 2017)
One of the premier peer-reviewed clinical journals in general and internal medicine, Mayo Clinic Proceedings is among the most widely read and highly cited scientific publications for physicians, with a circulation of approximately 125,000. Mayo Clinic Proceedings is published by Elsevier and sponsored by Mayo Clinic and the Mayo Foundation for Medical Education and Research. The mission of Mayo Clinic Proceedings is to promote the best interest of patients by advancing the knowledge and professionalism of the physician community. Since 2009 the Journal has offered CME credit for specific articles from both the Mayo Clinic for Concise Review for Clinicians and specially commissioned Symposia articles (comprehensive coverage on one topic).
Participation in this activity consists of reviewing articles and responding to a short online test. It is estimated that this activity will take approximately one hour per article. There is no charge for participating in this Journal CME activity.
To receive CME credit, please do the following:
- Click Take Course
- Complete quiz and evaluation (There is a required 80% pass rate in order to earn credit, with 1 retake allowed.)
- Print your Record of Attendance
Questions? cme@mayo.edu
Target Audience
The target audience for Mayo Clinic Proceedings is primarily internal medicine physicians and other clinicians who wish to advance their current knowledge of clinical medicine and who wish to stay abreast of advances in medical research.
Learning Objectives
Learning Objectives: On completion of this article, you should be able to: (1) recognize the basis for the amyloid hypothesis regarding the pathogenesis of Alzheimer disease and current approaches to disease modifying therapy; (2) contrast the impact of multiple genetic risk factors identified in genome wide screening analyses with the major autosomal dominant forms as well as apolipoprotein E ɛ4; (3) correlate imaging biomarkers with the neuropathology of Alzheimer disease; and (4) recognize the extended preclinical course of Alzheimer disease, its neuropathological basis, and its expression in the form of biomarkers.
DISCLOSURE SUMMARY:
No relevant financial relationships:
Planning Committee, Editorial Board Members and Staff
Thomas J. Beckman, M.D.
Timothy B. Curry, M.D., Ph.D.
William L. Lanier, Jr., M.D.
Terry Jopke
Eric L. Matteson, M.D.
Karl A. Nath, M.D.
S. Vincent Rajkumar, M.D.
Kimberly D. Sankey
Nicki Smith
A. Keith Stewart, M.D.
Margaret (Peg) Wentz
Christopher M. Wittich, M.D.
Relevant financial relationships:
Editorial Board
Michelle Mauermann, M.D. - Consultant - IONIS Pharmaceuticals, Honoraria - Continuum
Off-label drugs: None.
AUTHORS DISCLOSURE SUMMARY:
Authors: Richard J. Caselli, MD1; Thomas G. Beach, MD, PhD2; David S. Knopman, MD3; and Neill R. Graff-Radford, MD4
Affiliations: Department of Neurology, Mayo Clinic Arizona1, Rochester3, and Florida4 Civin Laboratory for Neuropathology, Sun Health Research Institute2
Conflicts of Interest:
Dr. Caselli is an investigator in clinical trials sponsored by Merck and Novartis; and receives research support from NIA P30AG19610, NIA R01AG031581, and the Arizona Alzheimer’s Consortium.
Dr. Beach is an investigator in clinical trials sponsored by Avid Radiopharmaceuticals and Navidea Biopharmaceuticals, has served as a consultant for Avid Radiopharmaceuticals and GE Healthcare; and receives or has received research support from the NIH, grants U24NS072026, P30 AG19610, R01 AG044372, R21NS093222 and R21AG044723, the Michael J. Fox Foundation for Parkinson’s Research, and the Arizona Alzheimer’s Consortium.
Dr. Knopman serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and the DIAN study; is an investigator in clinical trials sponsored by Biogen, TauRX Pharmaceuticals, Lilly Pharmaceuticals, and the Alzheimer’s Disease Cooperative Study; and receives research support from the NIH, grants P50 AG16574, U01 AG06786 and, R01 AG41851.
Dr. Graff Radford is an investigator in clinical trials sponsored by Biogen, Lilly, TauRX and Axovant; and he has served as a consultant for Cytox.
Off-label drugs: Antipsychotic drugs as a class for the treatment of agitation and psychosis in patients with dementia.
Manufacturer(s)/Provider(s): Pfizer, Novartis, Janssen, Forest
Product(s)/Device(s): cholinesterase inhibitors, memantine
Accreditation Statement:
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Statement(s):
AMA
Mayo Clinic College of Medicine and Science designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
Other Health Care Professionals
A certificate of attendance will be provided to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here.
Available Credit
- 1.00 ABIM
- 1.00 AMA PRA Category 1 Credit™